Lebanon
Tuberculosis profile
Population  2012 4.6 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.072 (0.038–0.12) 1.5 (0.81–2.5)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.16 (0.12–0.2)
Prevalence  (includes HIV+TB) 0.95 (0.39–1.7) 20 (8.5–37)
Incidence  (includes HIV+TB) 0.73 (0.64–0.83) 16 (14–18)
Incidence (HIV+TB only) 0.041 (0.036–0.047) 0.88 (0.77–1)
Case detection, all forms (%) 86 (76–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 240 (39) Relapse 9 (100)
Smear-negative 131 (21) Treatment after failure 0 (0)
Smear-unknown / not done 0 (0) Treatment after default 0 (0)
Extrapulmonary 250 (40) Other 0 (0)
Other 0 (0)      
Total new 621   Total retreatment 9  
           
Other (history unknown) 0        
Total new and relapse 630   Total cases notified 630  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 0.6 0.5 0.5
Age < 15 4 14 27
Laboratories 2012
Smear (per 100 000 population) 6.0
Culture (per 5 million population) 3.2
Drug susceptibility testing (per 5 million population) 1.1
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 80   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 77  
Retreatment 100  
TB/HIV 2012 Number (%)
TB patients with known HIV status 424 (67)
HIV-positive TB patients 3 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 3 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 9  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.1 (0.13–3.8) 67 (22–96)
MDR-TB cases among notified pulmonary
TB cases
4 (0–14) 6 (2–9)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 10 (4%) 6 (67%) 16
Laboratory-confirmed MDR-TB cases 2 4 6
Patients started on MDR-TB treatment     6
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 97%
% Funded internationally  
% Unfunded 3%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-18 Data: www.who.int/tb/data